Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)

Who can take part

• Patients aged >=18 years at enrollment
• Patients diagnosed with asthma with an ACQ -5 score ≥1.5 at enrollment
• Patients who are judged to newly initiate BGF MDI (320/28.8/9.6 ug) treatment as per the investigator's decision and are able to initiate inhalation on the same day as the prescription or, if they have already used another inhaled medication on that day, on the following day
• Patients who are capable to fill PRO physically and mentally as judged by investigator
• Patients who are assessed as able to visit the study site during the 8-week follow-up period
• Patients who provide written informed consent

Who cannot take part

• Patients who have been treated with ICS/LABA/LAMA within 6 months before enrollment
• Patients who have history of asthma exacerbation within 4 weeks before enrollment
• Patients who have history of respiratory infection within 4 weeks before enrollment
• Patients who are prescribed systemic corticosteroids within 4 weeks before enrollment
• Patients who have been treated with any biologic therapy for asthma (e.g., anti-IgE, anti-IL-5/IL-5R, anti-IL-4R, anti-TSLP) within 1 year before enrollment
• Patients who have participated in any interventional studies within 1 year before enrollment
• Patients who are pregnant, lactating or intending to become pregnant during the study period